ASA reduces the risk of death or developing MI by about 50% (compared to no anti-

platelet therapy) in patients with NSTE ACS. Therefore, ASA remains the cornerstone of early treatment for all ACS.43 Dosing of ASA for NSTE ACS is the same as that for STE ACS (Table 8-2). ASA is continued indefinitely.


For patients with NSTE ACS, clopidogrel added to ASA and started on the first day of hospitalization as a 300 to 600 mg loading dose and followed the next day by 75

mg orally per day is recommended for most patients.2 Clopidogrel, administered as a

300 mg loading dose followed by 75 mg once daily for at least 1 month and up to 12

months is recommended in patients who do not undergo a coronary stent placement, because its use reduces the combined risk of death from cardiovascular causes, non-


fatal MI, or stroke by 20%. , In patients who undergo a coronary stent placement,

it should be used in a similar fashion as described for STEMI. ' Because of the potential for increased risk of bleeding, clopidogrel should be discontinued for at least 5

days before elective CABG surgery. Glycoprotein IIb/IIIa Receptor Inhibitors

In patients with NSTE ACS scheduled for early PCI, administration of either abcix-imab or eptifibatide (double bolus) at the time of PCI is recommended. The use of tirofiban in these patients is not recommended, because it has been shown to be inferior to abciximab. Medical therapy with either eptifibatide or tirofiban in patients without a planned PCI or as therapy started before PCI is reserved for higher-risk patients, such as those with positive troponin or ST-segment depression, and patients who have continued or recurrent ischemia despite other antithrombotic therapy. Ab-ciximab started as medical therapy prior to proceeding to PCI should not be used because it has not been shown to be beneficial in that setting.2

Doses and contraindications to glycoprotein IIb/IIIa receptor inhibitors are described in Table 8-2. Major bleeding and rates of transfusion are increased with administration of a glycoprotein IIb/IIIa receptor inhibitor in combination with ASA and an anticoagulant,2 but there is no increased risk of intracranial hemorrhage in the absence of concomitant fibrinolytic treatment. The risk of thrombocytopenia with tirofiban and eptifibatide is lower than that with abciximab. Bleeding risks appear similar between agents.


The choice of anticoagulant for a patient with NSTE ACS is guided by risk stratification, treatment strategy, and the results of recent clinical trials.2,44-46 For patients undergoing an early invasive strategy with early coronary angiography and PCI, either UFH, LMWH, low-dose fondaparinux or bivalirudin should be administered. If fonda-parinux is chosen for a patient who undergoes PCI, it should be administered in com bination with UFH as the dose of fondaparinux studied appears too low to prevent thrombotic events during PCI. UFH is the preferred anticoagulant following angio-graphy in patients subsequently undergoing CABG during the same hospitalization.

Patient Encounter 2, Part 1

RR is a 66-year-old, 90-kg (198-lb) male who presents to the emergency department by ambulance complaining of 4 hours of continuous chest pressure that started while mowing the lawn. RR developed substernal chest pressure about 30 minutes after starting to mow his lawn. He stopped and rested but the chest pressure did not resolve. Local paramedics were summoned and he was given three 0.4 mg sublingual nitroglycerin tablets by mouth, 325 mg ASA by mouth, and morphine 2 mg IV push without relief of chest discomfort.

PMH: HTN for 5 years; type 2 DM for 5 years

FH: Father with myocardial infarction at age 75; mother and sister alive with type 2 DM

SH: Nonsmoker Allergies: NKDA

Meds: Metformin 1,000 mg by mouth twice daily; ASA 325 mg by mouth once daily; lisinopril 20 mg by mouth once daily

ROS: 10/10 chest pain/squeezing

HEENT: Normocephalic atraumatic

CV: Regular rate and rhythm S1 S2, -S3, -S4, no murmurs or rubs

Lungs: Clear to auscultation and percussion

Abd: Nontender, nondistended

Gl: Normal bowel sounds

GU: Stool guaiac negative

Exts: No bruits, pulses 2+, femoral pulse present, good range of motion Neuro: Alert and oriented x 3, cranial nerves intact

Labs: Sodium 136 mEq/L (136 mmol/L), potassium 4.0 mEq/L (4.0 mmol/L), chloride 105 mEq/L (105 mmol/L), bicarbonate 22 mEq/L (24 mmol/L), SCr 1.0 mg/dL (88 pmol/L), glucose 160 mg/dL (8.9 mmol/L), WBC 6.9 x 103mm3 (6.9 x 109L), hemoglobin 14.7 g/dL (147 g/L or 9.1 mmol/L), hematocrit 42%, platelets 320 x 103/mm3 (320 x 109L), troponin I 10 ng/mL (10 mcg/L), oxygen saturation 99% on room air

ECG: Normal sinus rhythm, PR 0.16 seconds, QRS 0.08 seconds, QTc 0.38 seconds, occasional polymorphic premature ventricular contractions, 2 mm ST-segment depression inferior leads

CXR: Normal

What type of ACS is this?

What information is suggestive of acute MI?

In patients in whom an initial conservative strategy is planned (i.e., are not anticipated to receive angiography and revascularization), either enoxaparin, UFH or low-dose fondaparinux is recommended. Bivalirudin has not been studied in this setting. Because there are more data supporting the use of enoxaparin, it is the preferred LMWH for ACS.

In comparative trials, the rate of bleeding with enoxaparin has been higher than other anticoagulants. For patients presenting with NSTE ACS in whom cardiologists suspect a high risk for bleeding while receiving an anticoagulant, fondaparinux (for conservatively managed patients) and bivalirudin (for interventionally managed patients) are the preferred anticoagulants recommended by the ACC/AHA NSTE ACS guidelines. Neither fondaparinux or bivalirudin are FDA approved for NSTE ACS despite being recommended by the ACC/AHA NSTE ACS guidelines.

Guideline recommended dosing and contraindications are described in Table 8-2. Because LMWHs are eliminated renally and patients with renal insufficiency generally have been excluded from clinical trials, some practice protocols recommend UFH for patients with creatinine clearance (CrCl) rates of less than 30 mL/min. (CrCl is

calculated based on total patient body weight using the Cockroft-Gault equation. ) However, while recommendations for dosing adjustment of enoxaparin in patients with CrCl between 10 and 30 mL/min are listed in the product manufacturer's label, the safety and efficacy of LMWH in this patient population remain vastly understudied. Administration of LMWHs should be avoided in dialysis patients with ACS. It is unclear whether or not bivalirudin requires dose adjustment for patients with sig nificant renal dysfunction. While bivalirudin is eliminated renally, the duration of infusion in recent trials has been short (several hours only), and therefore the actual need for dosing adjustment is unlikely. Patients with serum creatinine (SCr) greater than 3.0 mg/dL (265 ^mol/L) were excluded from ACS trials with fondaparinux and the product label states that fondaparinux is contraindicated in patients with CrCl less than 30 mL/min and in patients weighing less than 50 kg (110 lb).

UFH is monitored and the dose adjusted to a target aPTT, whereas LMWHs are administered by a fixed, actual body weight-based dose without routine monitoring of antifactor Xa levels. Some experts recommend antifactor Xa monitoring for LMWHs in patients with renal impairment during prolonged courses of administration of more than several days. No monitoring of coagulation is recommended for bivalirudin and fondaparinux.

The Prevention and Treatment of Headaches

The Prevention and Treatment of Headaches

Are Constant Headaches Making Your Life Stressful? Discover Proven Methods For Eliminating Even The Most Powerful Of Headaches, It’s Easier Than You Think… Stop Chronic Migraine Pain and Tension Headaches From Destroying Your Life… Proven steps anyone can take to overcome even the worst chronic head pain…

Get My Free Audio Book

Post a comment